- Home
- CSR vs GYRE Comparison
CSR vs GYRE Comparison
Compare CSR & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSR
- GYRE
- Stock Information
- Founded
- CSR 1970
- GYRE 2002
- Country
- CSR United States
- GYRE United States
- Employees
- CSR N/A
- GYRE N/A
- Industry
- CSR Real Estate Investment Trusts
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- CSR Real Estate
- GYRE Health Care
- Exchange
- CSR Nasdaq
- GYRE Nasdaq
- Market Cap
- CSR 1.0B
- GYRE 897.1M
- IPO Year
- CSR N/A
- GYRE N/A
- Fundamental
- Price
- CSR $60.32
- GYRE $7.49
- Analyst Decision
- CSR Buy
- GYRE
- Analyst Count
- CSR 8
- GYRE 0
- Target Price
- CSR $72.13
- GYRE N/A
- AVG Volume (30 Days)
- CSR 116.9K
- GYRE 189.9K
- Earning Date
- CSR 08-04-2025
- GYRE 08-12-2025
- Dividend Yield
- CSR 5.11%
- GYRE N/A
- EPS Growth
- CSR N/A
- GYRE N/A
- EPS
- CSR N/A
- GYRE 0.02
- Revenue
- CSR $263,570,000.00
- GYRE $100,643,000.00
- Revenue This Year
- CSR $4.84
- GYRE $21.04
- Revenue Next Year
- CSR $3.58
- GYRE $89.64
- P/E Ratio
- CSR N/A
- GYRE $93.64
- Revenue Growth
- CSR 2.19
- GYRE N/A
- 52 Week Low
- CSR $54.13
- GYRE $6.11
- 52 Week High
- CSR $76.16
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- CSR 40.28
- GYRE 42.81
- Support Level
- CSR $59.53
- GYRE $7.49
- Resistance Level
- CSR $60.94
- GYRE $7.80
- Average True Range (ATR)
- CSR 1.41
- GYRE 0.48
- MACD
- CSR -0.15
- GYRE 0.07
- Stochastic Oscillator
- CSR 21.41
- GYRE 40.48
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.